RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR T-Cell therapy offers hope for children with relapsed blood cancers
Disease control Recruiting nowThis study tests a new treatment called AUTO1 (Obe-cel) for children and teens with certain types of blood cancer that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attac…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
New hope for Hard-to-Treat lymphomas: drug trial targets relapsed patients
Disease control Recruiting nowThis study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors or stop the cancer from growing. About 27 participants wi…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 11:09 UTC
-
New hope for tough lymphoma: early trial of YK012 begins
Disease control Recruiting nowThis early-phase study tests a new drug called YK012 in 48 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will receiv…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 20, 2026 12:05 UTC
-
New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests MK-1045, an immunotherapy that helps the immune system fight cancer, in people with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to treatment. About 100 participants will receive the drug to find the safest dose and check for si…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC